Date: 2013-01-08
Type of information: Nomination
Compound:
Company: Hoopika Biotech (Austria)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 8, 2013, Hookipa Biotech announced the appointment of two new members to its Management team: Thomas P. Monath as Chief Medical Officer and Farshad Guirakhoo as Chief Scientific Officer.
Dr. Thomas P. Monath, serving as consulting Chief Medical Officer will play a key role in setting up Hookipa´s R&D strategies and product development processes. Dr. Monath is a former partner in the Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers, and also Adjunct Professor at the Harvard School of Public Health. He has served on numerous government and international committees on infectious diseases and biosecurity, World Health Organization expert committees and the (U.S) National Vaccines Advisory Committee. Between 1992 and 2006, Dr. Monath was Chief Scientific Officer and Executive Director of Acambis where he pioneered the development of numerous vaccines against various infectious diseases. Acambis was acquired by the vaccine giant Sanofi Pausteur in 2008 for £ 285 million.
Dr. Guirakhoo serving as Chief Scientific Officer will be responsible for all aspects of researchand development activities at Hookipa. Prior to joining Hookipa, Dr. Guirakhoo held the position of Senior Director of External Research and Development at Sanofi Pasteur. Before his appointment at Sanofi in 2007, he spent 15 years with vaccine biotech Acambis, where he headed research and co-invented the ChimeriVax-technology platform.
Financial terms:
Latest news:
